In this seminar, Professor McGarity describes the preemption war and analyzes the relevant issues in the context of federal regulation of pharmaceutical products. He argues that during the George W. Administration, the FDA has dramatically departed from its traditional hands-off policy with regard to federal preemption of state common law claims in the context of pharmaceuticals approved by that agency. No substantive change in the relevant statute, regulations, or case law has prompted the agency's aggressive new stance on preemption. Rather, he argues that the FDA's new stance is primarily motivated by the outgoing Administration's decision to bypass Congress in its eagerness to implement a long-standing "tort reform" agenda.
Professor McGarity also argues that the Bush Administration has not limited its aggressive efforts to preempt state tort law to FDA regulation. The National Highway Traffi c Safety Administration, the Consumer Product Safety Commission, and the Federal Railroad Commission have adopted similar stances under their statutes, all of which contain express preemption clauses. As Professor McGarity argues in greater detail in his forthcoming book, "The Preemption War: When Federal Bureaucracies Trump Local Juries," he believes the outcome of this war is critical to the ability of the common law to provide corrective justice to injured plaintiffs and protective justice for those of us who have not yet been injured but are at risk from products and activities that are otherwise subject to federal regulation. 
